MLH1 and pancreatic neoplasm: A recent prospective observational study of 3119 MMR-mutation carriers found the cumulative incidence for colon cancer, endometrial cancer, and pancreatic cancer in germline MLH1 mutation to be 25.7% (95% CI: 20.7–30.7%), 18.7% (95% CI: 12.9–24.5%), and 1.1% (95% CI: 0.0–2.1%) by age 50, respectively, and 41.6% (95% CI: 35.2–48.0%), 40.3% (95% CI: 31.5–49.1%), and 3.9% (95% CI: 1.4–6.4%) by age 70, respectively.